Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 1
2008 2
2009 2
2010 3
2011 7
2012 5
2013 13
2014 12
2015 17
2016 21
2017 24
2018 37
2019 26
2020 42
2021 27
Text availability
Article attribute
Article type
Publication date

Search Results

215 results
Results by year
Filters applied: . Clear all
Page 1
Tyrosine kinase SYK is a potential therapeutic target for liver fibrosis.
Qu C, Zheng D, Li S, Liu Y, Lidofsky A, Holmes JA, Chen J, He L, Wei L, Liao Y, Yuan H, Jin Q, Lin Z, Hu Q, Jiang Y, Tu M, Chen X, Li W, Lin W, Fuchs BC, Chung RT, Hong J. Qu C, et al. Hepatology. 2018 Sep;68(3):1125-1139. doi: 10.1002/hep.29881. Epub 2018 May 21. Hepatology. 2018. PMID: 29537660 Free PMC article.
Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers.
Houlihan CF, Vora N, Byrne T, Lewer D, Kelly G, Heaney J, Gandhi S, Spyer MJ, Beale R, Cherepanov P, Moore D, Gilson R, Gamblin S, Kassiotis G, McCoy LE, Swanton C; Crick COVID-19 Consortium, Hayward A, Nastouli E; SAFER Investigators. Houlihan CF, et al. Lancet. 2020 Jul 25;396(10246):e6-e7. doi: 10.1016/S0140-6736(20)31484-7. Epub 2020 Jul 9. Lancet. 2020. PMID: 32653078 Free PMC article. No abstract available.
CYLD-mediated signaling and diseases.
Mathis BJ, Lai Y, Qu C, Janicki JS, Cui T. Mathis BJ, et al. Among authors: qu c. Curr Drug Targets. 2015;16(4):284-94. doi: 10.2174/1389450115666141024152421. Curr Drug Targets. 2015. PMID: 25342597 Free PMC article. Review.
Capturing roaming molecular fragments in real time.
Endo T, Neville SP, Wanie V, Beaulieu S, Qu C, Deschamps J, Lassonde P, Schmidt BE, Fujise H, Fushitani M, Hishikawa A, Houston PL, Bowman JM, Schuurman MS, Légaré F, Ibrahim H. Endo T, et al. Among authors: qu c. Science. 2020 Nov 27;370(6520):1072-1077. doi: 10.1126/science.abc2960. Science. 2020. PMID: 33243885
Scalable and robust SARS-CoV-2 testing in an academic center.
Aitken J, Ambrose K, Barrell S, Beale R, Bineva-Todd G, Biswas D, Byrne R, Caidan S, Cherepanov P, Churchward L, Clark G, Crawford M, Cubitt L, Dearing V, Earl C, Edwards A, Ekin C, Fidanis E, Gaiba A, Gamblin S, Gandhi S, Goldman J, Goldstone R, Grant PR, Greco M, Heaney J, Hindmarsh S, Houlihan CF, Howell M, Hubank M, Hughes D, Instrell R, Jackson D, Jamal-Hanjani M, Jiang M, Johnson M, Jones L, Kanu N, Kassiotis G, Kirk S, Kjaer S, Levett A, Levett L, Levi M, Lu WT, MacRae JI, Matthews J, McCoy LE, Moore C, Moore D, Nastouli E, Nicod J, Nightingale L, Olsen J, O'Reilly N, Pabari A, Papayannopoulos V, Patel N, Peat N, Pollitt M, Ratcliffe P, Reis E Sousa C, Rosa A, Rosenthal R, Roustan C, Rowan A, Shin GY, Snell DM, Song OR, Spyer MJ, Strange A, Swanton C, Turner JMA, Turner M, Wack A, Walker PA, Ward S, Wong WK, Wright J, Wu M; Crick COVID-19 Consortium. Aitken J, et al. Nat Biotechnol. 2020 Aug;38(8):927-931. doi: 10.1038/s41587-020-0588-y. Nat Biotechnol. 2020. PMID: 32555528 No abstract available.
215 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page